| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1800 | 2016 |
| Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study HS Hochster, LL Hart, RK Ramanathan, BH Childs, JD Hainsworth, ... Journal of Clinical Oncology 26 (21), 3523-3529, 2008 | 955 | 2008 |
| Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil … ML Rothenberg, AM Oza, RH Bigelow, JD Berlin, JL Marshall, ... Journal of Clinical Oncology 21 (11), 2059-2069, 2003 | 837 | 2003 |
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial JR Infante, LA Fecher, GS Falchook, S Nallapareddy, MS Gordon, ... The lancet oncology 13 (8), 773-781, 2012 | 575 | 2012 |
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non … RS Herbst, VJ O'Neill, L Fehrenbacher, CP Belani, PD Bonomi, L Hart, ... Journal of Clinical Oncology 25 (30), 4743-4750, 2007 | 478 | 2007 |
| Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind … RS Herbst, R Ansari, F Bustin, P Flynn, L Hart, GA Otterson, G Vlahovic, ... The Lancet 377 (9780), 1846-1854, 2011 | 439 | 2011 |
| Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. S Khambata-Ford, CT Harbison, LL Hart, M Awad, LA Xu, CE Horak, ... Oncology, 2008 | 331 | 2008 |
| Overall survival with ribociclib plus letrozole in advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, L Hart, ... New England Journal of Medicine 386 (10), 942-950, 2022 | 291 | 2022 |
| Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors DD Von Hoff, MM Mita, RK Ramanathan, GJ Weiss, AC Mita, PM LoRusso, ... Clinical Cancer Research 22 (13), 3157-3163, 2016 | 257 | 2016 |
| Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a … KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ... JAMA oncology 4 (10), 1344-1351, 2018 | 197 | 2018 |
| A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer J Berlin, JC Bendell, LL Hart, I Firdaus, I Gore, RC Hermann, MF Mulcahy, ... Clinical Cancer Research 19 (1), 258-267, 2013 | 192 | 2013 |
| A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer AA Chiappori, T Kolevska, DR Spigel, S Hager, M Rarick, S Gadgeel, ... Annals of oncology 26 (2), 354-362, 2015 | 171 | 2015 |
| Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial A Grothey, LL Hart, KM Rowland, RH Ansari, SR Alberts, NM Chowhan, ... Journal of Clinical Oncology 26 (15_suppl), 4010-4010, 2008 | 150 | 2008 |
| Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial JM Weiss, T Csoszi, M Maglakelidze, RJ Hoyer, JT Beck, MD Gomez, ... Annals of Oncology 30 (10), 1613-1621, 2019 | 141 | 2019 |
| Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy GV Burton, LL Hart, GS Leight JR, JD Iglehart, KS McCarty JR, EB Cox Cancer 63 (11), 2088-2092, 1989 | 135 | 1989 |
| Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final … I Smith, D Yardley, H Burris, R De Boer, D Amadori, K McIntyre, ... | 120 | 2017 |
| Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer J Bendell, M Saleh, AAN Rose, PM Siegel, L Hart, S Sirpal, S Jones, ... Journal of Clinical Oncology 32 (32), 3619-3625, 2014 | 119 | 2014 |
| Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 JT Beck, GN Hortobagyi, M Campone, F Lebrun, I Deleu, HS Rugo, ... Breast cancer research and treatment 143, 459-467, 2014 | 119 | 2014 |
| Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised … F Saad, K Fizazi, V Jinga, E Efstathiou, PC Fong, LL Hart, R Jones, ... The Lancet Oncology 16 (3), 338-348, 2015 | 114 | 2015 |
| Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial J O’shaughnessy, K Petrakova, GS Sonke, P Conte, CL Arteaga, ... Breast cancer research and treatment 168, 127-134, 2018 | 113 | 2018 |
